160 related articles for article (PubMed ID: 35484517)
1. Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.
Kazama H; Kawaguchi O; Seto T; Suzuki K; Matsuyama H; Matsubara N; Tajima Y; Fukao T
BMC Cancer; 2022 Apr; 22(1):470. PubMed ID: 35484517
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
Suzuki K; Matsubara N; Kazama H; Seto T; Tsukube S; Matsuyama H
Jpn J Clin Oncol; 2019 Dec; 49(12):1157-1163. PubMed ID: 31361807
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m
Matsuyama H; Matsubara N; Kazama H; Seto T; Tsukube S; Suzuki K
BMC Cancer; 2020 Jul; 20(1):649. PubMed ID: 32660451
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan.
Matsubara N; Suzuki K; Kazama H; Tsukube S; Seto T; Matsuyama H
J Geriatr Oncol; 2020 Sep; 11(7):1067-1073. PubMed ID: 32198082
[TBL] [Abstract][Full Text] [Related]
5. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
Matsuyama H; Matsubara N; Kazama H; Seto T; Sunaga Y; Suzuki K
BMC Cancer; 2023 Jun; 23(1):538. PubMed ID: 37308888
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance.
Matsubara N; Matsuyama H; Kazama H; Seto T; Sunaga Y; Suzuki K
Jpn J Clin Oncol; 2024 Jan; 54(1):97-102. PubMed ID: 37807695
[TBL] [Abstract][Full Text] [Related]
9. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T; Uemura H; Sumitomo M; Harada K; Sugimoto M; Hayashi N; Yoshimura K; Fukasawa S; Ecstein-Fraisse E; Sunaga Y; Oya M
Jpn J Clin Oncol; 2019 Aug; 49(8):766-771. PubMed ID: 31329922
[TBL] [Abstract][Full Text] [Related]
10. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
11. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Rouyer M; Oudard S; Joly F; Fizazi K; Tubach F; Jove J; Lacueille C; Lamarque S; Guiard E; Balestra A; Droz-Perroteau C; Fourrier-Reglat A; Moore N;
Br J Cancer; 2019 Dec; 121(12):1001-1008. PubMed ID: 31719685
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
Kosaka T; Shinojima T; Morita S; Oya M
Cancer Sci; 2018 May; 109(5):1570-1575. PubMed ID: 29493842
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
Miyoshi Y; Sakamoto S; Kawahara T; Uemura K; Yokomizo Y; Uemura H
Urol Int; 2019; 103(3):279-284. PubMed ID: 31461725
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy.
Iwamoto H; Kano H; Shimada T; Naito R; Makino T; Kadomoto S; Yaegashi H; Shigehara K; Izumi K; Kadono Y; Mizokami A
In Vivo; 2021; 35(3):1703-1709. PubMed ID: 33910855
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study.
Takai M; Kato S; Nakano M; Fujimoto S; Iinuma K; Ishida T; Taniguchi M; Tamaki M; Uno M; Takahashi Y; Komeda H; Koie T
Asia Pac J Clin Oncol; 2021 Jun; 17(3):238-244. PubMed ID: 32970933
[TBL] [Abstract][Full Text] [Related]
16. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer.
Fujiwara M; Yuasa T; Yasuoka S; Komai Y; Oguchi T; Fujiwara R; Numao N; Yamamoto S; Yonese J
Cancer Chemother Pharmacol; 2021 Sep; 88(3):525-531. PubMed ID: 34110449
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
[TBL] [Abstract][Full Text] [Related]
18. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullén A
Eur J Cancer; 2018 Jul; 97():33-40. PubMed ID: 29685343
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
Med Oncol; 2019 Feb; 36(4):32. PubMed ID: 30815799
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
Yasuoka S; Yuasa T; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2019 Oct; 39(10):5803-5809. PubMed ID: 31570485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]